Zacks Investment Research
11 Dec 2025, 18:01 UTC · 47w ago
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Impact · against what's priced in
The upgrade of Elicio Therapeutics to a Zacks Rank #2 (Buy) based on positive earnings estimate revisions provides a short-term bullish signal. However, as a quantitative rating change based on analyst consensus, the material impact is limited.
- ELTX+0.20
No priced-in read yet
- In context
The stock is upgraded to a Buy rating following an upward trend in earnings estimates, which the analyst suggests correlates with near-term price increases.
Read from the article alone
Top 1 mover · tap to explore
